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The Journal of Immunology
Characterization and Application of a Unique Panel of
Monoclonal Antibodies Generated against Etanercept
Iris Detrez,* Els Brouwers,* Miet Peeters,* Nick Geukens,† Kurt de Vlam,‡ and
Ann Gils*
The clinical response in ankylosing spondylitis (AS) patients treated with biologic agents can be influenced by pharmacokinetic
variability among and within these patients. Therapeutic drug monitoring is seen as a valuable tool to improve patient care.
The aim of this study was to generate a panel of mAbs toward etanercept (ETN) and to determine ETN and anti-ETN concen-
trations in AS patients. mAbs against ETN (MA-ETN) were generated using hybridoma technology. For quantification of ETN
concentrations, a mAb-based TNF-coated ELISA and a mAb/mAb-based sandwich-type ELISAwere developed. For evaluation of
the anti-ETN Ab response, a bridging ELISA, as well as a functional cell-based assay, were constructed. Disease activity of the AS
patients was measured with the AS Disease Activity Score (ASDAS). Active disease was defined as ASDAS ‡ 2.1. A total of 59 of 76
generated mAbs were ETN specific and were characterized further. Fifty-one mAbs revealed inhibitory properties in a cell-based
assay. Analysis of serum concentrations of 21 ETN-treated AS patients with the TNF/MA-ETN68C5-HRP ELISA and the MA-
ETN63C8/MA-ETN61C1-HRP ELISA revealed a good Pearson’s r (+0.974) but a poor intraclass correlation coefficient (+0.528)
as the result of underestimation of the values in the former ELISA. At 24 wk, ETN concentrations were similar in patients with
ASDAS < 2.1 and ‡ 2.1. Anti-ETN Abs were not detected in any of the patient samples tested. In conclusion, highly sensitive mAb-
based immunoassays were developed for quantification of ETN and anti-ETN concentrations. The impact of these methods needs
to be evaluated further in clinical practice. The Journal of Immunology, 2016, 196: 2879–2884.
A
nkylosing spondylitis (AS), the most common form of
spondyloarthritis, is characterized by chronic inflam-
mation of the spine and the sacroiliac joints. However, in
a substantial number of patients, peripheral arthritis and dif-
ferent extra-articular manifestations add to the burden of disease
(1). Until recently, the therapeutic options for AS have been
limited to nonsteroidal anti-inflammatory drugs and physio-
therapy because conventional disease-modifying anti-rheumatic
drugs showed no or inconsistent effects. In contrast, the intro-
duction of biological drugs heralded a new era for the treatment
of AS (1, 2). Etanercept (ETN; Enbrel) is a fully human dimeric
fusion protein that specifically binds to TNF, thereby modu-
lating its biologic function and preventing its proinflammatory
activities (3). Despite its proven efficacy in AS, the clinical
response to treatment varies (4).
Currently, anti-TNF drugs are dosed using a one-size-fits-all
approach, whereby patients receive the same or similar dose
regimen, regardless of any variables that might affect the phar-
macokinetic profile of the drug (5). Nonetheless, inadequate anti-
TNF drug concentrations and the presence of antidrug Abs
(ADAbs) frequently have been implicated as predisposing factors
for therapeutic failure and side effects (6). Furthermore, a recent
study by Kneepkens et al. (4) provided evidence for a significant
association among disease activity, inflammation, and ETN con-
centrations in patients with AS at 24 wk of treatment.
However, therapeutic drug monitoring (TDM) of anti-TNF
therapy has not been used in routine clinical practice of AS.
This lack of implementation may be explained, in part, by dis-
crepancies between the existing TDM platforms, which hamper the
interpretation of drug concentrations and highlights the need for
standardization. In addition, the lack of a “gold standard” for
ADAb measurements makes comparison between different assays
even more complex.
The main objective of this work was to develop highly sensitive
immunoassays for the specific quantification of serum ETN and
anti-ETN concentrations by taking advantage of a newly generated
and extensively characterized panel of mouse mAbs. The clinical
significance of the assays was additionally evaluated using serum
samples from 21 AS patients receiving ETN maintenance dosing
(50 mg/wk).
Materials and Methods
BSA, HRP, H2SO4, and citric acid were purchased from Sigma-Aldrich
(Steinheim, Germany). VWR International (Haasrode, Belgium) delivered
Na2HPO4·2H2O. KH2PO4 and Sulfo-NHS-LC-Biotin were obtained from
Thermo Fisher Scientific (Waltham, MA). HRP-conjugated streptavidin
was purchased from IBL International (Hamburg, Germany), and
recombinant human TNF and sTNF receptor type II were from PeproTech
(London, U.K.). H2O2 was obtained from Merck (Darmstadt, Germany),
and o-phenylenediamine was from Acros Organics (Geel, Belgium). ETN
was purchased as Enbrel from Pfizer SA/NV (Elsene, Belgium).
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Patients
Serum samples were collected from 21 patients with AS under ETN
maintenance therapy (50 mg ETN s.c. once a week) at the Department of
Rheumatology, University Hospitals Leuven - campus Gasthuisberg. The
samples were taken at their first hospital visit and at 24 wk of follow-up,
without reference to the timing of the administration of their therapy
(i.e., trough/nontrough not specified). Three of these patients administered
the drug themselves before the first sample was taken; the other patients
were anti-TNF naive. Disease activity was assessed at baseline and after
6 mo of anti-TNF therapy using the AS Disease Activity Score (ASDAS)
(7). Active disease was defined as ASDAS $ 2.1 (8). The study was ap-
proved by the Ethical Committee UZ Leuven (S51013/S55065). Informed
consent was provided by all patients.
mAb generation
Hybridomas producing mAbs were generated in-house upon immunization
of SJL/J mice with ETN. The details of this protocol were described by Van
Stappen et al. (9). Positive clones were selected, after which the cross-
reactivity of the MA-ETN toward infliximab (Remicade), adalimumab
(Humira), golimumab (Simponi), and a human IgG mixture (Multigam)
was determined. The hybridomas that reacted exclusively with ETN were
grown in Integra CELLine systems (Wheaton Industries, Millville, NJ) for
large-scale production. The MA-ETN were purified from conditioned
medium on a ProSep-vA Ultra column (Millipore, Billerica, MA) and
conjugated with HRP.
Characterization of mAbs directed toward ETN
Neutralizing capacity. The neutralizing capacity of the mAbs against ETN
(MA-ETN) was assessed in a cell-based assay (CBA). HT1080 (American
Type Culture Collection) is a human fibrosarcoma cell line that expresses
IL-6 upon stimulation with TNF. The TNF-inducible IL-6 secretion is
inhibited by ETN. A neutralizing Ab can upregulate IL-6 expression by
blocking the inhibitory effect of ETN on TNF. We described the details
of this assay previously (10). MA-ETN, used in a 10-fold molar excess
(150 ng/ml) over ETN, were added to sera supplemented with TNF
(7.5 ng/ml, based on the TNF EC50/80) and ETN (15 ng/ml, based on the
ETN IC50/80) after which the effect on IL-6 expression was determined. An
MA-ETN was considered to be neutralizing when$80% of the initial IL-6
response could be retrieved.
Epitope binning. Epitope binning was carried out using competition ELISA
(9). The MA-ETN (“cold” Abs) were tested against all HRP-conjugated
MA-ETN (“labeled” Abs) in a pairwise combinatorial manner to determine
region binding areas recognized by the two Abs relative to each other. For
this, ETN was coated on the plate (at a concentration of 4 mg/ml), and the
MA-ETN were added in excess (10 mg/ml) to the wells before the HRP-
conjugated MA-ETN (0.025 mg/ml) were applied. The defined epitope
regions were considered to be independent when the OD obtained for the
labeled Ab in the presence (+) of cold Ab was $80% of its OD obtained in
the absence (2) of cold Ab.
Affinity determination. Surface plasmon resonance–based affinity mea-
surements of the selected MA-ETN were carried out using a Biacore
3000 (GE Healthcare, Uppsala, Sweden). Briefly, CM5 sensor chips
were immobilized to 6 50 resonance units with ETN using
N-hydroxysuccinimide/1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride amine coupling chemistry. Then, the MA-ETN were
applied at five concentrations between 50 and 1000 nM at a flow rate of
60 ml/min. Analysis of the association and dissociation rates was
performed using BIAevaluation software (1:1 Langmuir binding global
fit isotherm).
Isotyping. The isotypes of the selected MA-ETN were determined using the
IsoStrip Mouse Monoclonal Antibody Isotyping Kit (Roche Diagnostics,
Vilvoorde, Belgium), according to the manufacturer’s protocol.
Determination of serum concentrations of ETN
TNF-coated ELISA. Measurement of ETN serum concentrations was ini-
tially carried out by means of a TNF-coated ELISA setup, which, in
principle, is similar to the test that is routinely used for quantification of
infliximab concentrations (9). A newly generated and extensively charac-
terized MA-ETN-HRP was used as conjugate. Performance characteristic
of the ETN dose-response curve in the range of 0.8–50.0 ng/ml was
evaluated by calculating the recovery percentage of three quality control
(QC) samples (high, mid, and low) in buffer. Acceptance criterion was
defined as an absolute mean percentage deviation # 20% for each QC
sample. The cut-off of the assay was set to have an upper negative limit of
99.7%, determined using the mean (+ 3 SD) OD of the anti-TNF naive AS
patient samples (200-fold diluted).
Sandwich-type ELISA. ETN concentrations were also determined in a newly
developed sandwich-type ELISA, based on the principle that ETN is
captured between an immobilized MA-ETN and an added HRP-labeled
MA-ETN that targets a different epitope on the ETN molecule. Briefly,
96-well plates were precoated with an MA-ETN and blocked with 1% BSA
in PBS (pH 7.4) to minimize nonspecific protein binding. After washing,
serum samples (1000-fold diluted) were added, and the plates were incu-
bated overnight at 4˚C. Bound ETN was subsequently detected by HRP-
labeled MA-ETN. Plates were developed using o-phenylenediamine and
H2O2 in sodium citrate, disodium phosphate buffer (pH 5), and the reaction
was stopped with H2SO4. The absorbance was measured at 490 nm with an
ELx808 Absorbance Microplate Reader (BioTek Instruments, Winooski,
FIGURE 1. Flow chart of the gener-
ation and characterization of MA-ETN.
FIGURE 2. ETN concentrations of the 21 AS patients at 24 wk of
treatment. ETN concentrations were measured with the mAb-based TNF-
coated ELISA (dashed gray line) and the mAb-based sandwich-type
ELISA (solid black line). All 21 patients were stratified according to ETN
concentration (low to high) in the sandwich-type ELISA, with each data
point representing the mean ETN concentration (n = 3).
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VT), and the results were compared with a dose-response curve of ETN
(0.2–10.0 ng/ml concentration range), present on each plate. Standard
curve performance and cut-off of the assay were worked out analogously to
the TNF-coated ELISA.
Assessment of MA-ETN
Bridging ELISA. The panel of in-house developed MA-ETN was further
evaluated as calibrator in a bridging ELISA setup for quantification of the
ADAb response toward ETN. This immunoassay depends on the bivalency
of the MA-ETN and, hence, their ability to “bridge” an ETN molecule
preabsorbed to a plastic plate with an added biotin-labeled ETN molecule.
The use of biotin offered the advantage of a signal-amplification step when
bound by HRP-conjugated streptavidin and o-phenylenediamine, sequen-
tially applied on the 96-well plate (11). The MA-ETN calibration curve
was applied in the range of 0.2–10.0 ng/ml, and three QC samples (high,
mid, and low) were prepared in buffer to test its performance. The cut-off
of the assay was established using the anti-TNF naive AS patient samples
in a 20-fold dilution.
Cell-based assay. The same calibrator of the bridging ELISA was addi-
tionally evaluated in the in-house developed functional CBA to quantify
the neutralizing Ab responses elicited to ETN. Although this technique is
labor intensive and shows a large interassay variability (10), it has the
advantage that both low- and high-affinity neutralizing Abs of different
subtypes (including IgG4) can be measured. To determine the half-
maximal inhibitory concentration (IC50) of the calibrator, serial concen-
trations (0–240 ng/ml) were added to sera supplemented with 7.5 ng/ml
TNF and 15 ng/ml ETN. The cut-off value of the CBA was calculated by
using the anti-TNF naive AS patient samples in a 40-fold dilution under
the same conditions as described above.
Statistical analyses
Quantitative data were summarized as mean and SD or median and
interquartile range (IQR), as appropriate. The Shapiro–Wilk normality test
was used to assess the normality of continuous variables. Univariate sta-
tistical analyses were performed using GraphPad Prism 5 (GraphPad, San
Diego, CA). The paired t test and Wilcoxon matched-pairs signed-rank test
were used to compare paired data. The unpaired t test and the Mann–
Whitney U test were used to compare unpaired data. The Pearson corre-
lation test was used to analyze correlation. A two-sided p value, 0.05 was
considered statistically significant.
Results
Generation and characterization of the MA-ETN
Four fusions of Sp2/0-Ag14 myeloma cells with spleen cells
isolated from immunized SJL/J mice yielded a total of 76 positive
hybridoma clones producing mAbs toward ETN (Fig. 1). Of these
Abs, 78% (59/76) showed no (cross-)reactivity with any of the
other anti-TNF drugs nor with the human IgG mixture and were
considered ETN specific. The 59 ETN-specific mAbs were suc-
cessfully purified from conditioned medium and subjected to an
in-depth characterization (Fig. 1). A first evaluation of their neu-
tralizing capacity revealed that the majority (51 of 59, 86%)
strongly inhibited the TNF–ETN interaction. For the remaining
eight (14%) MA-ETN, no inhibitory effect was observed (Fig. 1).
The 51 neutralizing MA-ETN were further assigned to 12 distinct
clusters based upon their binning profiles. The MA-ETN with no
inhibitory properties eventually fell into five unique epitope bins
(Fig. 1).
Determination of serum concentrations of ETN
TNF-coated and sandwich-type assay performance validation.
Fifty-nine MA-ETN belonging to 17 clusters were tested for their
suitability as conjugate in the construction of a TNF-coated ELISA
for quantification of ETN serum concentrations. Based upon the
sensitivity and specificity of the obtained response, only the
noninhibitory MA-ETN68C5-HRP proved to be useful for fur-
ther evaluation of the assay. The ETN calibration curve was
nonlinear between 0.8 and 50.0 ng/ml, and the assay cut-off was set
at 0.2 mg/ml (taking into account a serum dilution factor of 1:200).
The three QC samples, final concentrations of 40, 20, and 10 ng/ml,
yielded recoveries of 89 6 5, 85 6 6, and 67 6 3%, respectively
(mean 6 SD, n = 3). For the construction of the sandwich-type
ELISA, a similar approach was used testing 17 MA-ETN 3 17
MA-ETN-HRP combinations to capture and detect ETN in this
setup. A high-affinity compatible pair of Abs (MA-ETN63C8/MA-
ETN61C1-HRP) was selected for development of the assay. Se-
lection was based on their strict specificity for ETN and on their
important neutralizing activity. Using this combination, a linear
dose-response curve was obtained in the range of 0.2–10.0 ng/ml.
The assay cut-off was set at 0.2 mg/ml (taking into account a serum
dilution factor of 1:1000). The recoveries of the three QC samples,
final concentrations of 8, 4, and 2 ng/ml, were 94 6 4, 95 6 4, and
95 6 6%, respectively (mean 6 SD, n = 3), indicating that the
sandwich-type ELISA is accurate and closely reflects the amount of
ETN present in the sample.
Comparative analysis of 21 AS patient samples at 24 wk of
follow-up. A significant and high correlation was observed be-
tween the two in-house–developed ELISA methods (sandwich
versus TNF coated) for measuring serum ETN concentrations
(r = +0.974, p , 0.0001). Nevertheless, mean ETN concentration
was considerably higher in the sandwich-type ELISA (3.8 mg/ml,
SD 2.2 mg/ml) compared with the TNF-coated ELISA (1.9 mg/ml,
SD 1.2 mg/ml) (p, 0.0001). Fig. 2 shows the ETN concentrations
(low to high) in the 21 patients with AS at 24 wk of treatment.
Based upon an intraclass correlation coefficient of 0.528, the
methods cannot be considered interchangeable (12).
Extensive evaluation of the newly developed sandwich-type
ELISA. To confirm that ETN concentrations were not markedly
overestimated in the sandwich-type ELISA and to further evaluate
FIGURE 3. Dose-response curve of MA-ETN64A5. To determine the
inhibitory effect of MA-ETN64A5, different concentrations (0–240 ng/ml)
of MA-ETN64A5 were added to sera supplemented with 7.5 ng/ml TNF
and 15 ng/ml ETN. Data are mean 6 SD (n = 3).
FIGURE 4. Drug-interference effect in the bridging ELISA. Percentage
recovery of 80 ng/ml MA-ETN64A5 (solid black line) and 2000 ng/ml
MA-ETN68C5 (dashed gray line) after incubation with a titration of ETN
(n = 2).
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the performance of the assay, some additional experiments were
conducted. Effective prevention of nonspecific binding was
assessed by means of a competition experiment using a 6-fold
molar excess of MA-ETN61C1 (the conjugate Ab of the assay)
over ETN. For this purpose, a patient sample with a measured ETN
concentration of 1 mg/ml was selected. The sample was incubated
for 20 min at 37˚C in the presence and absence of 6 mg/ml MA-
ETN61C1, followed by measurement of the concentration in the
sandwich-type ELISA. Addition of 6 mg/ml MA-ETN61C1
revealed a response below the cut-off of the assay (data not
shown). Accuracy and imprecision of the assay were determined
by analyzing seven replicates of each QC sample in triplicate. The
experiments were performed in buffer and in patient sera. All QC
samples reached the minimum acceptable criteria: an absolute
mean percentage deviation # 20% (for accuracy) and a coefficient
of variation # 15% (for imprecision). To exclude interference of
endogenous sTNF receptor type II, serial 2-fold dilutions of 50 ng/ml
recombinant sTNF receptor type II were applied on the MA-
ETN63C8/MA-ETN61C1-HRP combination, revealing a 100-
fold lower reactivity compared with ETN, with a reactivity similar
to background from 6.25 ng/ml onward (data not shown).
Assessment of MA-ETN
Bridging and CBA performance validation. Of all MA-ETN that
were able to cross-link coated ETN with biotin-labeled ETN, MA-
ETN64A5 was selected as calibrator in the bridging ELISA. MA-
ETN64A5 is a high-affinity and inhibitory IgG1 anti-ETN Ab with
k L chains that specifically binds to ETN. With the use of MA-
ETN64A5 as calibrator, a linear dose-response curve was obtained
in the range of 0.2–10.0 ng/ml. The cut-off of the assay was set at
3.2 ng/ml equivalents MA-ETN64A5 (taking into account a serum
dilution factor of 1:20), and its performance was established by
the recoveries of the three QC samples (data not shown). As-
sessment of the inhibitory effect of MA-ETN64A5 in the CBA
revealed an IC50 of 10.8 ng/ml upon addition of 7.5 ng/ml TNF
and 15 ng/ml ETN (Fig. 3). Using the anti-TNF naive AS patient
samples, the cut-off in the CBAwas subsequently set at 200 ng/ml
equivalents MA-ETN64A5 (taking into account a serum dilution
factor of 1:40).
Comparative analysis of 21 AS patient samples at 24 wk of
follow-up. Patients’ sera were first analyzed in the bridging
ELISA. However, no anti-ETN Abs were detected. Because the
maintenance regimen for AS patients treated with ETN requires
weekly dosing, collection of patient samples with undetectable
serum ETN concentrations is a challenge. To ensure reliable as-
sessment in the CBA, the anti-TNF naive patient samples and their
corresponding follow-up samples (all containing measurable ETN
concentrations) were applied to the HT1080 cells. Basal IL-6
concentrations were 1.4 6 0.5 ng/ml (mean 6 SD). Upon addi-
tion of 7.5 ng/ml TNF to individual serum samples, the increased
IL-6 production was set at 100% for each anti-TNF naive patient
sample, and IL-6 production of the follow-up sample was calcu-
lated versus this 100%. For 94% (17/18) of the samples, addition
of the follow-up sample revealed an IL-6 response that was 69 6
18% (mean 6 SD) lower than the response of its naive sample,
indicating the presence of functionally active ETN. When an ad-
ditional 15 ng/ml ETN was added to the sera, IL-6 production
decreased to background concentrations in all patient samples
(data not shown).
Extensive evaluation of the bridging ELISA. The detection of
ADAbs is affected by excess of the drug in the sample itself. To test
the performance of the bridging ELISA in the presence of serum
ETN, a noninhibitory (MA-ETN68C5) and an inhibitory (MA-
ETN64A5) anti-ETN mAb were selected and preincubated with
graded concentrations of ETN, and the reduction in signal
was evaluated. The noninhibitory MA-ETN68C5 demonstrated
a lower affinity for ETN (KA = 3.2 3 10
7 M21) compared with
MA-ETN64A5 (KA = 7.7 3 10
8 M21), and a concentration of
2000 ng/ml was required to give a signal above the cut-off in the
bridging ELISA. As shown in Fig. 4, a 10-fold molar excess of
ETN over both MA-ETN completely abolished the binding and
resulted in undetectable MA-ETN concentrations. Accuracy and
imprecision of the assay were determined analogously to the
sandwich-type ELISA. All QC samples reached the minimum
acceptable criteria (data not shown).
Analysis of AS patient samples
A total of 21 AS patients with an ASDAS of 3.86 1.2 (mean6 SD)
was included in this study. The baseline disease status of these
patients is shown in Table I. Treatment with ETN resulted in
general improved outcomes compared with baseline (ASDAS
of 1.8 6 1.3). Nevertheless, at 24 wk of therapy, 8 of the 21
ETN-treated AS patients had a high disease activity indicated
by ASDAS $ 2.1. As shown in Table II, there was no significant
difference in baseline clinical and biochemical characteristics
between patients with ASDAS $ 2.1 (at 24 wk) and patients
with ASDAS , 2.1 (at 24 wk). At week 24, the mean ETN
Table I. Disease status of the 21 AS patients at baseline and at 24 wk of
therapy
Variables Baseline 24 Wk
BASDAI (Q2, Q3, Q6) 7.0 (5.5–8.0) 3.0 (1.0–4.0)*
PG DAS 7.0 (4.5–8.0) 2.0 (1.0–5.0)*
CRP 11.7 (4.5–20.6) 1.3 (0.6–7.4)*
ESR 27.0 (21.5–47.0) 10.0 (4.0–20.0)*
Data are expressed as median (IQR). Normal CRP , 3.0 mg/l; normal ESR , 10
mm/h.
*p , 0.05.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index (0–10): Back pain,
BASDAI Q2; peripheral pain/swelling, BASDAI Q3; duration of morning stiffness,
BASDAI Q6; PG DAS, Patient Global Disease Activity Score (0–10).
Table II. Clinical and biochemical characteristics for patients with ASDAS , 2.1 (n = 13) and ASDAS $ 2.1 (n = 8)
Variables
ASDAS , 2.1 (at 24 wk) ASDAS $ 2.1 (at 24 wk)
Baseline 24 Wk Baseline 24 Wk
BASDAI (Q2, Q3, Q6; median [IQR]) 7.0 (4.5–8.0) 1.0 (0.5–3.0)* 7.0 (6.0–9.5) 4.0 (3.3–7.5)*
PG DAS (mean [SD]) 6.0 (2.6) 1.8 (1.4)* 7.0 (1.3) 5.1 (2.7)*
CRP (median [IQR]) 11.7 (2.1–28.0) 0.6 (0.2–1.3)* 11.6 (10.3–19.4) 9.7 (3.0–23.5)
ESR (median [IQR]) 26.0 (18.0–68.5) 6.0 (3.0–13.5)* 36.0 (26.0–45.0) 20.0 (11.5–36.3)
ETN (mg/ml; mean [SD])a 3.8 (2.5) 3.9 (1.6)
aMeasured with the mAb-based sandwich-type ELISA.
*p , 0.05.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index (0–10): Back pain, BASDAI Q2; peripheral pain/swelling, BASDAI Q3; duration of morning stiffness,
BASDAI Q6; PG DAS, Patient Global Disease Activity Score (0–10).
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concentration was similar for both groups. However, for patients
with ASDAS $ 2.1, the two nonpatient-reported measurements,
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR),
were not significantly improved from baseline (Table II).
Discussion
The importance of TDM of anti-TNF agents has attracted con-
siderable attention in recent years. Several clinical studies strongly
suggest that a personalized approach to chronic disease manage-
ment, in which therapeutic decisions are not based solely on as-
sessment of clinical symptoms but also on drug and ADAb
determinations, will result in safer and more (cost-)effective patient
care (13–15). Nonetheless, conflicting reports originating from the
use of inadequately designed assays might complicate the reli-
ability of TDM in everyday clinical practice of AS. The aim of the
current study was to develop highly sensitive immunoassays for
the specific quantification of serum ETN and anti-ETN concen-
trations by taking advantage of a newly generated and extensively
characterized panel of mouse mAbs.
For the measurement of ETN serum concentrations, two ELISA
types were developed. Performance validation of the TNF/MA-
ETN68C5-HRP ELISA yielded poor recoveries in a spiking ex-
periment with three ETN concentrations. This is in contrast to the
recovery experiments in the MA-ETN63C8/MA-ETN61C1-HRP
ELISA for which good results were obtained. The reason for the
underestimation in the TNF-coated ELISA is unclear, but it might
be attributable to some nonspecific conformational changes in the
TNF molecules immobilized on the 96-well plate. In this regard, it
is commonly believed that ETN binding is restricted to the trimer
form of TNF, with receptor binding site(s) in the cleft formed
between two TNF subunits (16). It is possible that these binding
sites became less accessible when TNF was coated on the plate. In
contrast, for the anti-TNF mAbs (e.g., golimumab), a high intra-
class correlation coefficient agreement was obtained between the
respective ELISA types (17). However, these anti-TNF mAbs are
known to bind both monomeric and trimeric forms of TNF (16).
Applying the MA-ETN63C8/MA-ETN61C1-HRP ELISA, mean
ETN concentration in the 21 AS patient samples was 3.8 mg/ml
(SD 2.2 mg/ml) at 24 wk of treatment. This finding is more or less
in line with previous studies in AS (4, 18–20), in which mean ETN
concentrations of ∼3 mg/ml were reported at 24 wk of therapy. In
these studies, ETN was also captured through its ability to bind
TNF; however, the set-up differed slightly from the TNF-coated
ELISA described in this article, because a specific mouse mAb
was used to immobilize TNF on the plate. To exclude interference
of endogenous sTNF receptor type II, recombinant sTNF receptor
type II was applied on the ELISA combination, revealing a 100-
fold lower response compared with ETN. Taking into account that
the reported sTNF receptor type II concentration in AS patients is
2.8 ng/ml (21), and thus ∼1000-fold lower compared with the
mean serum ETN concentration of 3.8 mg/ml (SD 2.2 mg/ml) in
our cohort of AS patients, interference of endogenous sTNF re-
ceptor type II in the detection of ETN using the MA-ETN63C8/
MA-ETN61C1-HRP ELISA can be ruled out.
The inhibitory MA-ETN64A5, generated in the study, was
equally well suited to quantify the total amount of anti-ETNAbs in
a bridging ELISA as to determine the proportion of neutralizing
anti-ETN Abs in a functional CBA. However, anti-ETN Abs were
not detected in any of the patient sera tested, which seems to
support the hypothesis that ETN is not or only marginally im-
munogenic (18). Although there is a possibility that some positive
results were missed as a result of interference of drug in the
sample, the overall reported frequency of anti-ETN Abs is low
(19). In each case in which anti-ETN Abs were detected, these
Abs tended not to neutralize the drug’s biological activity or
compromise its long-term effectiveness (19, 20).
In contrast to Kneepkens et al. (4), we did not find any difference
in ETN concentrations between patients with ASDAS , 2.1 and
patients with ASDAS $ 2.1 at 24 wk of therapy. However, for
patients with ASDAS $ 2.1, the two objective parameters of in-
flammation, CRP and ESR, did not improve significantly from
baseline. This is notable because ETN is specifically engineered
to treat inflammation, and it raises the question of whether
therapy should be discontinued in such patients because of lack
of efficacy. Theoretically, there are many reasons for ETN non-
responsiveness, with a non-TNF–driven disease phenotype being
one of the possibilities (22). This so-called “true” nonresponse
to ETN therapy (despite adequate concentrations of drug) could
have impaired the interpretation of the pharmacokinetic relation-
ships between response and remission. Other factors, associated
with low drug concentrations (e.g., patient-specific characteris-
tics) (23), and, thus, an incomplete suppression of TNF activity
(also referred to as a “partial” nonresponse), could not be
assessed in this study. Moreover, given the small number of
patients and the random timing of sampling, these data must be
interpreted with caution.
In conclusion, highly sensitive mAb-based immunoassays were
developed for the specific quantification of serum ETN and anti-
ETN concentrations and applied to a cohort of 21 AS patients.
However, further research is needed to evaluate the impact of these
methods in clinical decision-making for AS patients when added to
current practice.
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